Abstract The Survodutide 10mg peptide pen (also known as BI 456906) represents a significant advancement in metabolic research, functioning as a novel dual agonist of the Glucagon Receptor (GCGR) and the Glucagon-like Peptide-1 (GLP-1) receptor. Unlike “twincretins” (GLP-1/GIP), Survodutide integrates the anorexigenic (appetite-suppressing) effects of GLP-1 with the profound energy-expenditure properties of Glucagon. This 10mg formulation is specifically optimised for initial-phase investigation and dose-escalation studies. It allows researchers to explore the delicate balance between glucagon-mediated lipolysis/thermogenesis and GLP-1 mediated glycaemic control, offering a unique window into the mechanisms of non-shivering thermogenesis and hepatic lipid clearance in models of metabolic dysfunction-associated steatohepatitis (MASH).

Mechanism and Research Interest

Primary Biological Pathway: The “Energy Wasting” Mechanism The primary research interest in Survodutide is its activation of the Glucagon receptor. Historically, glucagon was viewed solely as a hyperglycaemic agent. However, Survodutide utilises glucagon agonism to stimulate mitochondrial uncoupling in brown adipose tissue (BAT), increasing basal metabolic rate (BMR). By pairing this with GLP-1 agonism, which suppresses appetite and stimulates insulin secretion, Survodutide creates a “negative energy balance” from two directions: reduced intake and increased output. The 10mg pen is used to map the precise threshold at which this thermogenic effect activates without triggering counter-regulatory hyperglycaemia.

Secondary Research Finding: Hepatic Autophagy and Lipid Oxidation Survodutide is a leading candidate for liver fibrosis research. The glucagon component is a potent driver of hepatic lipid oxidation and autophagy (cellular cleaning). In preclinical models, Survodutide has demonstrated the ability to rapidly clear ectopic fat from the liver. The 10mg formulation is critical for quantifying the rate of de novo lipogenesis reduction and observing histological improvements in liver stiffness markers (such as $\alpha$-SMA) over short-to-medium term studies.

Tertiary Research Finding: Glycaemic Stability via Counter-Balance A key physiological question is how Survodutide maintains euglycaemia despite administering a glucagon agonist. Research suggests that the GLP-1 component’s insulinotropic effect sufficiently counteracts the glycogenolytic effect of the glucagon component. Researchers use the 10mg pen to challenge this hypothesis in models of Type 2 Diabetes, monitoring continuous glucose profiles to verify that the net effect remains glucose-lowering despite the presence of the glucagon moiety.

Long-term Genomic and Safety Observations Given the potent activity on the liver, safety studies are paramount. Current research tracks markers of hepatocellular stress and proliferation. Transcriptomic analysis of hepatocytes exposed to Survodutide 10mg focuses on confirming the upregulation of oxidative phosphorylation genes while ensuring that genes associated with fibrosis or inflammation (Col1a1, Tgfb1) are downregulated. This genomic profiling is essential for establishing the long-term viability of GCGR/GLP-1 therapies.

Product Specifications

• Purity: Validated at >98+% via High-Performance Liquid Chromatography (HPLC). The acylated peptide structure is verified to ensure stability against enzymatic degradation by DPP-4.

• Appearance: The 3ml pen contains a clear, colourless, sterile liquid.

• Precision: The pen device features a micro-click adjustment, allowing for 0.25mg or 0.5mg dosing increments. This high resolution is vital for titration, as the Glucagon receptor can be sensitive to rapid dose escalations.

• Storage: The product must be stored at 2∘C to 8∘C.

Storage and Shipping Guidelines

Refrigeration and Shelf Life The Survodutide 10mg Pen relies on a stable tertiary structure to maintain dual-receptor affinity. It must be refrigerated (2∘C to 8∘C) immediately upon receipt. The shelf life is 12 months in the sealed state. Once the bacteriostatic seal is broken, the solution is stable for 28 days. Researchers should note that Glucagon-based peptides can be prone to fibrillation; therefore, the pen should not be shaken vigorously, and the full 10mg should be utilised within the 28-day window.

Shipping Stability We utilise medical-grade thermal packaging. The peptide is stable for up to 72 hours at ambient UK temperatures during transit. However, due to the specific sensitivity of the glucagon-binding domain, we strongly recommend “Next Day” delivery to ensure the reagent arrives with maximal bioactivity.

Freezing Warning Strictly avoid freezing. Freezing causes the formation of ice crystals that can denature the peptide. Upon thawing, a denatured peptide may form insoluble fibrils (appearing as cloudiness or floating strands). Such a product is biologically inactive and must be discarded.

Why Choose the Peptide Pro 3ml Pen Format?

The Survodutide 10mg Pen is the definitive tool for Proof-of-Concept Studies. Investigating Glucagon receptor agonism is complex; manual mixing errors can easily lead to overdosing, resulting in unwanted hyperglycaemic spikes in test subjects.

Our pre-calibrated pen format eliminates this risk. It provides a sterile, controlled delivery system that ensures the ratio of GLP-1 to Glucagon activity remains constant for every administration. This consistency is the only way to generate publishable data on the delicate “goldilocks zone” of dual-agonism.

For researchers expanding their metabolic portfolio, we recommend comparing data against:

• Tirzepatide 20mg: (To compare GLP-1/Glucagon vs. GLP-1/GIP).

• Cagrireta 15mg: (To compare Dual vs. Triple agonism).

Disclaimer

This product is strictly for Research Use Only (RUO). It is not intended for human consumption, injection, therapeutic use, or diagnostic procedures. The information provided is for educational and scientific reference only. Purchase is restricted to verified research institutions and qualified individuals. Any evidence of intended misuse for human application will result in immediate order cancellation and blacklisting, in compliance with UK research chemical regulations.